Stockscreener 앱 받기
4.25
6.59%
-0.30
시간 외 거래:
4.17
-0.08
-1.88%
Exagen Inc 주식(XGN)의 최신 뉴스
Exagen Inc. (XGN) Q1 2026 Earnings: Adjusted Loss Narrows, Stock Gains in AftermathSegment Revenue Breakdown - newsline.com
Exagen Shareholders Approve Directors, Auditor and Pay Package - The Globe and Mail
Exagen | 8-K: Current report - Moomoo
Exagen (NASDAQ: XGN) shareholders approve directors, auditor and say-on-pay - Stock Titan
Exagen Company Profile & Introduction - Moomoo
XGN Q1 2026 Earnings: EPS Beats Estimates Despite Stock DeclineRevenue Surprise History - newsline.com
Exagen Inc. Q1 2026 Earnings: EPS Surprise Lifts but Revenue Disclosure Gap Weighs on SharesMargin Compression Risk - newsline.com
Exagen Inc. (XGN) Plunges 9.4% – Key Support Levels in Focus After Sharp SelloffIV Spike - newsline.com
Exagen study shows lupus test identifies 25% more patients By Investing.com - Investing.com South Africa
Exagen study shows lupus test identifies 25% more patients - Investing.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus - GlobeNewswire
Lupus test used on 1M patients finds cases routine lab work misses - Stock Titan
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock DeclinesBook Value Growth - The Legal Advocate
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
How much upside is left in Exagen (XGN)? Wall Street analysts think 73.05% - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Yahoo Finance
Parian Ultreia reports 5.3% stake in Exagen (NASDAQ: XGN) - Stock Titan
Exagen Inc. Q1 2026 Earnings: EPS Beat Surprises, but Revenue Details AbsentEstimate Accuracy - The Legal Advocate
XGN Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Revenue UncertaintyEarnings Weakness Phase - Newser
Exagen Inc. (XGN) Holds Steady Near Support Amid Low VolatilityLiquidity Sweep - The Legal Advocate
Exagen Inc. (XGN) Inches Lower as Shares Test Key Support Near $4.05Institutional Volume - The Legal Advocate
William Blair Maintains Exagen(XGN.US) With Buy Rating - Moomoo
Exagen Inc. Common Stock (XGN) Stock Price Today & Analysis - Gotrade
Exagen Inc. (XGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Per Share - Newser
Earnings call transcript: Exagen Inc. beats Q1 2026 expectations, stock surges - Investing.com Nigeria
Exagen Inc stock (US30063K1051): 13G filing shows 9.9% stake - AD HOC NEWS
Exagen Earnings Call Highlights Growth Amid Headwinds - The Globe and Mail
EXAGEN (XGN) holder Jorey Chernett reports 2.41M shares, 9.9% - Stock Titan
Exagen (XGN) Rallies +8.02% as Bulls Target $3.96 2026-05-19Professional Trade Ideas - Newser
Exagen (XGN) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsEarnings Deceleration Risk - newsline.com
Exagen reaffirms $70M-$73M 2026 revenue guidance as it targets $600-$650 ASP over time - MSN
Why Exagen (XGN) Just Dropped -4.55% — What to Watch 2026-05-15TPO Profile - Newser
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Exagen Targets $73 Million Revenue for 2026 as Test Volumes Surge - HarianBasis.co
Exagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Exagen (XGN) Receives a Buy from BTIG - The Globe and Mail
TradingKey - TradingKey
Exagen Achieves Record Q1 Revenue Driven by AVISE CTD Adoption - HarianBasis.co
1.63%
2.88%
자본화:
|
볼륨(24시간):